Please ensure Javascript is enabled for purposes of website accessibility
ORIGINAL PAPER
Comparison of vancomycin serum levels prior to and post therapeutic drug monitoring in patients admitted to hospital
 
More details
Hide details
1
Department of Clinical Pharmacy, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
 
2
Infectious and Tropical Disease Research Centre, Health Research Institute, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
 
3
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
 
4
School of Pharmacy, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
 
 
Submission date: 2021-01-28
 
 
Final revision date: 2021-04-29
 
 
Acceptance date: 2021-06-08
 
 
Publication date: 2021-09-30
 
 
Medical Studies 2021;37(3):187-192
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Vancomycin is of clinical importance because it is the last line of defence against bacteria.
Aim of the research: To compare serum levels of vancomycin before and after therapeutic drug monitoring (TDM) by a pharmacist in hospitalized patients.

Material and methods:
This prospective interventional study was performed on 30 patients admitted to the Infectious Disease Ward of Ahvaz Razi Hospital in 2019. In order to determine serum levels, peripheral blood samples were taken from patients in 2 stages (2 ml each time) before and 3 days after changing dose of vancomycin. For the patients, a checklist including demographic and clinical information (case number, gender, age, weight, underlying disease, site of infection, prescription dose, serum level, and type of microorganism) was completed.

Results:
The mean age of patients was 44.67 years and 53.3% were female. Serum level of the drug in 86.66% of patients did not correspond to the therapeutic range. In 33.33% of patients the dose based on weight and GFR did not correspond to the optimum dose, and in 86.66% of patients the serum was not at the desirable level. Overall, 26 patients recovered and were discharged, and 4 patients, who had an undesirable level of serum, died. The results of the study showed that by calculating the dose according to the initial criteria, it did not reach the desired level, and the presence of different diseases in patients receiving vancomycin and different drugs makes TDM necessary.

Conclusions:
Because there is not much time to intervene due to discharging patients or discontinuation of medication, designing a system to accelerate the TDM process is suggested.
REFERENCES (15)
1.
Schäfer M, Schneider TR, Sheldrick GM. Crystal structure of vancomycin. Structure 1996; 4: 1509-1515.
 
2.
Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 2016; 7: 136-47.
 
3.
Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 123: 1143-1149.
 
4.
Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006; 12: 92-95.
 
5.
Steinmetz T, Eliakim-Raz N, Goldberg E, Leibovici L, Yahav D. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect 2015; 21: 665-73.
 
6.
Lopes Rocha JL, Kondo W, Kuchiki Baptista MD, Cunha CA, Flenik Martins LT. Brazil J Infect Dis 2002; 6: 196-200.
 
7.
Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
 
8.
Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Inter Med 2009; 24: 1-10.
 
9.
Taheri S, Hayatshahi A, Torkamandi H, Hadjibabaie M, Javadi MR. Vancomycin utilization review in patients undergoing bone marrow transplantation. J Pharm Care 2014; 2: 66-69.
 
10.
Arfa P, Karimi A, Rafiei Tabatabaei S, Fahimzad A, Armin S, Sistanizad M. A prospective study to assess vancomycin serum concentrations inpediatric patients with current dosing guidelines. Iran J Pharm Res 2016; 15: 341-346.
 
11.
Ghehi M T, Rezaee S, Hayatshahi A, Hadjibabaie M, Gholami K, Javadi M, Khoee SH, Radfar M, Esfandbod M, Ghavamzadeh A. Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation (HSCT). Int J Hematol Stem Cell Res 2013; 7: 1-9.
 
12.
Suryadevara M, Steidl KE, Probst LA, Shaw J. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. J Pediatr Pharmacol Ther 2012; 17: 159-165.
 
13.
Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in Iran. Iran J Pharm Res 2012; 11: 163-170.
 
14.
Salehifar E, Babamahmoodi F, Alikhani A, Ganji R, Fazli M, Drug FM. Drug utilization evaluation of vancomycin in a referral infectious center in mazandaran province. J Pharm Care 2014; 2: 55-59.
 
15.
Ayazkhoo L, Mousavi S, Ramazani F, Ayatollahi-Tafti M, Sa’dabadi Z, Sistanizad M. Vancomycin utilization evaluation: are we dosing appropriately? J Pharm Care 2013; 1: 149-152.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top